Episode 207


Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time


COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed


How the Pfizer vaccination’s lack of impact on transmission is not a cause for concern and was clearly communicated since its release. The main impact is the reduction of severity, hospitalisations and death, and the data for this hasn’t changed


How a nasal vaccination might be coming

Host: David Lim | Total Time: 21 mins

Guest: A/Prof Paul Griffin, Infectious Diseases Physician and Clinical Microbiologist

Register for our fortnightly FREE WEBCASTS
Every second Tuesday | 7:00pm-9:00pm AEDT

Click here to register for the next one

Episode 207
<ul>
<li>
Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time
</li>
<li>
COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed
</li>
<li>
How the Pfizer vaccination’s lack of impact on transmission is not a cause for concern and was clearly communicated since its release. The main impact is the reduction of severity, hospitalisations and death, and the data for this hasn’t changed
</li>
<li>
How a nasal vaccination might be coming
</li>
</ul>
Host: David Lim | Total Time: 21 mins
Guest: A/Prof Paul Griffin, Infectious Diseases Physician and Clinical Microbiologist
Register for our fortnightly FREE WEBCASTS Every second Tuesday | 7:00pm-9:00pm AEDT
<a href="https://www.healthed.com.au/webcast/">Click here to register for the next one</a>

Healthed's medical education channel features the latest high quality clinical interviews and lectures from leading experts in their field, offering health professionals a convenient new way to boost their knowledge.

Advertisement